Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

Completed · Phase 4 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of the study is to determine whether memantine delays the progression of driving impairment in patients with mild Alzheimer's Disease (AD).

Key facts

Study ID

NCT00476008

Run by

Florida Atlantic University

People needed

60

Starts

2007-07-01

Expected to finish

2012-10-01

Last updated by the study team

2014-08-11

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women ages 60 years of age and older
• Subjects must either be previously diagnosed with mild Alzheimer's Disease (AD) by a neurologist, psychiatrist, geriatrician, or be evaluated at a Memory Disorders Center prior to entry into the study
• Subjects must have a score of ≥ 23 on the Mini-Mental State Examination (MMSE) at the Screening Visit
• Subjects must receive a passing score on the DriveABLE test
• Female subjects must be at least 2 years post-menopausal or surgically sterile
• Written informed consent must be obtained from the subject prior to the initiation of any study specific procedures

You may not qualify if…

• Subjects who have been treated with a depot neuroleptic within six (6) months of the Screening Visit
• Subjects who fail the OPTEC vision test at the screening visit
• Subjects who score > 7 on the Hachinski Test at the screening visit
• Subjects with evidence of clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease (subjects with controlled hypertension, right bundle branch block [complete or partial] and pacemakers may be included in the study). Subjects with thyroid disease may also be included in the study, provided they are euthyroid on treatment. Subjects with controlled diabetes may also be included
• Recent (< 2years) B12 or folate deficiency that was considered clinically significant
• Subjects with evidence of other psychiatric/neurologic disorders including, but not limited to, stroke, Vascular Dementia, Lewy-Body Disease, Parkinson's Disease, seizure disorder, head injury with loss of consciousness within the past 5 years, any psychotic disorder, or bipolar disorder
• Subjects who are taking, or have taken, amantadine, ketamine, dextromethorphan that cannot be discontinued or switched to an allowable alternative medication prior to the minimum allowable interval before Baseline
• Subjects who have been in an investigational drug study or who have received treatment with an investigational drug within 30 days (or 5 half-lives, whichever is longer) of the Screening Visit
• Any condition, which would make the subject, in the opinion of the investigator, unsuitable for the study
• If subjects are taking Acetylcholinesterase inhibitors (AChEls), they must be on a stable dose for > 3 months prior to baseline. No initiation of AChEls is permitted; discontinuation and dose reduction are permitted

Where it is running

• Charles E. Schmidt College of Medicine, Florida Atlantic University — Boca Raton, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.